INDP (Indaptus Therapeutics) Beginning Cash Position: $8.51 Mil (As of Mar. 2026)


INDP Indaptus Therapeutics Inc INDP
26 GF Score
Price $2.50
! 1 Warning Sign
View Full Analysis

What is Indaptus Therapeutics Beginning Cash Position?

Indaptus Therapeutics INDP +2.04% 26 Beginning Cash Position is $8.51 Mil as of Mar. 2026. GuruFocus rates INDP with a GF Score™ of 26/100. The stock has 1 warning sign investors should review.

Indaptus Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2026 was $8.51 Mil.

Indaptus Therapeutics's quarterly Beginning Cash Position declined from Sep. 2025 ($6.16 Mil) to Dec. 2025 ($5.83 Mil) but then increased from Dec. 2025 ($5.83 Mil) to Mar. 2026 ($8.51 Mil).

Indaptus Therapeutics's annual Beginning Cash Position increased from Dec. 2023 ($9.63 Mil) to Dec. 2024 ($13.36 Mil) but then declined from Dec. 2024 ($13.36 Mil) to Dec. 2025 ($5.79 Mil).

Indaptus Therapeutics Beginning Cash Position Related Terms

Indaptus Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Indaptus Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indaptus Therapeutics Beginning Cash Position Chart

Indaptus Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial 1.64 39.13 9.63 13.36 5.79

Indaptus Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.79 3.89 6.16 5.83 8.51
INDP
26GF Score
Indaptus Therapeutics Inc INDP
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Indaptus Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $8.51 Mil mean?
Indaptus Therapeutics (INDP) has a Beginning Cash Position of $8.51 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Indaptus Therapeutics and its competitors.
Is Indaptus Therapeutics' Beginning Cash Position too high?
Indaptus Therapeutics' current Beginning Cash Position is $8.51 Mil. Overall, Indaptus Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Indaptus Therapeutics' Beginning Cash Position compare to EDIT and ARTV?
Indaptus Therapeutics' Beginning Cash Position of $8.51 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Indaptus Therapeutics and its competitors. Indaptus Therapeutics's current Beginning Cash Position is $8.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indaptus Therapeutics stock overvalued right now?
Indaptus Therapeutics (INDP) has a current Beginning Cash Position of $8.51 Mil. The current Beginning Cash Position is $8.51 Mil. Indaptus Therapeutics' overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Indaptus Therapeutics (INDP), the current Beginning Cash Position is $8.51 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Indaptus Therapeutics Business Description

Address 3 Columbus Circle 15th Floor, New York, NY, USA, 10019
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
26GF Score

Get the complete analysis for INDP

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.50
Price